戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                  We reported previously that Janus kinase 3, a non-receptor tyrosine kinase, plays a
2 rotein, secreted frizzled-related protein 2, Janus kinase 3, and neutral sphingomyelinase 2 proteins
3 els trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling.
4 tion of STAT3 involves the tyrosine kinases, Janus Kinase-3 as well as Src kinase, whereas the Serine
5 orts, the nonreceptor tyrosine kinase, Jak3 (Janus kinase 3), does not regulate phosphorylation of vi
6 ations are usually absent in the SCID-X1 and Janus kinase 3 forms of SCID and greatly reduced in aden
7                     A selective inhibitor of Janus kinase 3 has now been generated and is effective f
8                     A selective inhibitor of Janus kinase 3 has now been generated and likely represe
9 A on Tyr(694) both in vitro and in vivo in a Janus kinase 3-independent fashion.
10 -beta-induced Treg development, and inhibits Janus kinase 3-induced STAT5 phosphorylation, a transcri
11 vide adequate immunosuppression, whereas the Janus kinase 3 inhibitor tofacitinib's success in the tr
12               In an effort to identify novel Janus kinase 3 inhibitors, a sequential focused screenin
13 ing is well known to regulate lymphopoiesis, Janus kinase 3 (JAK3) also plays a critical role in prom
14                           Phosphorylation of Janus kinase 3 (JAK3) and signal transducers and activat
15                                 Mutations in Janus kinase 3 (JAK3) are a cause of severe combined imm
16 e intermediate domain has been implicated in Janus kinase 3 (JAK3) association and activation.
17  SGs was prevented through the activation of Janus kinase 3 (JAK3) by the vitamin K3 analog menadione
18 es and tyrosine phosphorylation of STAT6 and Janus kinase 3 (JAK3) in NK and T cells.
19 se, p38 kinase, or phosphoinositol 3-kinase, Janus kinase 3 (JAK3) inhibition produced a significant
20 emistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550).
21 NK cells on SIV infection, use was made of a Janus kinase 3 (JAK3) inhibitor that has previously been
22 sus-host disease (GVHD) prophylaxis with the Janus kinase 3 (JAK3) inhibitor WHI-P131/JANEX-1 on the
23                                              Janus kinase 3 (Jak3) is a cytoplasmic tyrosine (Tyr) ki
24                                              Janus kinase 3 (Jak3) is a non-receptor tyrosine kinase
25                                              Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e
26                                              Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e
27                                              Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase e
28                          We report here that Janus kinase 3 (Jak3) is a primary response gene for int
29                                              Janus kinase 3 (Jak3) is a tyrosine kinase expressed in
30 irement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinica
31          Although constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the me
32                                              Janus kinase 3 (JAK3) mediates signal transduction from
33 ling pathway mutations, including activating Janus kinase 3 (JAK3) mutations, were detected.
34 cy (SCID) patients who exhibited 9 different Janus kinase 3 (JAK3) mutations.
35 microarray-based analyses and showed reduced Janus kinase 3 (JAK3) phosphorylation upon activation.
36                                              Janus kinase 3 (Jak3) plays a central role in the transd
37 mitogen-activated protein kinase (MAPK), and Janus kinase 3 (JAK3) signaling are necessary for F. tul
38                                          The Janus kinase 3 (JAK3) tyrosine kinase is mutated in 10%
39                                              Janus kinase 3 (JAK3), a member of the Janus family prot
40 ession of a catalytically inactive mutant of Janus kinase 3 (Jak3), and increased in 32D/c-Met cells
41 L7 cells by IL-7 leads to phosphorylation of Janus kinase 3 (JAK3), signal transducer and activator o
42 genesis of colon cancer, nor has the role of Janus kinase 3 (JAK3), the physiological activator of ST
43  phospholipase D2 (PLD2) is under control of Janus kinase 3 (JAK3), which mediates chemotaxis.
44 lso report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating P
45 eficiency (SCID) can be caused by defects in Janus kinase 3 (JAK3)-dependent cytokine signaling pathw
46 nt mutations all resulted in abnormal B-cell Janus kinase 3 (JAK3)-dependent interleukin-2 (IL-2)-ind
47  receptor common gamma chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T c
48 ), DNA-dependent protein kinase (prkdc), and janus kinase 3 (jak3).
49 he IL-2R-associated protein tyrosine kinase, Janus kinase 3 (Jak3).
50 mmac) cytokine-receptor-induced signaling by Janus kinase 3 (Jak3)/stimulators and activators of tran
51                                              Janus kinase-3 (JAK3) deficiency has recently been ident
52                               We report that Janus kinase 3 plays a role in mast cell-mediated bacter
53 rine systems that in turn activate the Jak3 (Janus kinase 3)/STAT5 (signal transducers and activators

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。